<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855344</url>
  </required_header>
  <id_info>
    <org_study_id>Ling Zhou</org_study_id>
    <nct_id>NCT04855344</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation Therapy and Intestinal Microbiota</brief_title>
  <official_title>Effect of Deep Brain Stimulation Therapy on Intestinal Microbiota in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to observe the changes of intestinal microbiota after deep brain stimulation&#xD;
      (DBS) therapy for Parkinson's disease, and explore the role of intestinal microbiota in the&#xD;
      neuroprotective effect of DBS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gut microbiota</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy</time_frame>
    <description>Analyzed by 16sRNA sequencing of feces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gut microbiota</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy</time_frame>
    <description>Analyzed by 16sRNA sequencing of feces</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood biomarkers of neuroinflammation and alpha-synuclein</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy</time_frame>
    <description>Comparing the changes of blood biomarkers such as neuroinflammation (TNF-alpha, IL-6, LPS) and alpha-synuclein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood biomarkers of neuroinflammation and alpha-synuclein</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy</time_frame>
    <description>Comparing the changes of blood biomarkers such as neuroinflammation (TNF-alpha, IL-6, LPS) and alpha-synuclein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of defecation</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of defecation</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of anti-Parkinson's agent</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of anti-Parkinson's agent</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the score of Unified Parkinson's Disease Rating Scales</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy</time_frame>
    <description>It is consisted of six scales, each scale is graded on a scale of 5 (0-4), with zero being normal and 4 being severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the score of Unified Parkinson's Disease Rating Scales</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy</time_frame>
    <description>It is consisted of six scales, each scale is graded on a scale of 5 (0-4), with zero being normal and 4 being severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39)</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy</time_frame>
    <description>Change in PDQ-39 scores, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39)</measure>
    <time_frame>Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy</time_frame>
    <description>Change in PDQ-39 scores, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Deep Brain Stimulation</condition>
  <condition>Gastrointestinal Microbiome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Parkinson's disease and are expected to undergo DBS therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt; 18 years of age;&#xD;
&#xD;
          2. Primary Parkinson's disease diagnosed according to British Brain Bank criteria (Hoehn&#xD;
             and Yahr);&#xD;
&#xD;
          3. Deep brain stimulator therapy;&#xD;
&#xD;
          4. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of probiotics or probiotics during the study;&#xD;
&#xD;
          2. Use antibiotics against intestinal bacteria at present or within the last 1 month;&#xD;
&#xD;
          3. With cognitive dysfunction or mental illness;&#xD;
&#xD;
          4. With severe diseases or is not expected to survive for more than a year;&#xD;
&#xD;
          5. A history of gastrointestinal surgery;&#xD;
&#xD;
          6. AIDS patients, hepatitis B/C positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cunming Liu</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Zhou</last_name>
    <phone>+8615895918786</phone>
    <email>lingzhou531@foxmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Hospital Research Ethics Committee of the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Wang</last_name>
      <email>jsphkjwy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

